Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals’ SEC disclosures can span hundreds of pages filled with immunology terms like C3 inhibition, trial cohort data, and royalty math with Swedish Orphan Biovitrum. Finding the cash runway or safety signals for SYFOVRE often means combing through dense footnotes. That complexity is exactly the problem investors face when they ask, “Where do I see Apellis Pharmaceuticals’ quarterly earnings report 10-Q filing?” or “How do I track Apellis Pharmaceuticals insider trading Form 4 transactions?”
Stock Titan solves this with AI-powered summaries that translate biotech jargon into clear language. Our platform delivers real-time feeds from EDGAR so you get every Form 4 insider transaction the moment it posts, plus side-by-side analytics that flag option exercises and executive stock transactions. Need the latest Apellis Pharmaceuticals annual report 10-K simplified? Our AI surfaces R&D spend, pipeline milestones, and geographic atrophy market commentary in seconds. Looking for material trial results? The Apellis Pharmaceuticals 8-K material events are explained, highlighting endpoints and FDA interactions.
Because the value of Apellis hinges on clinical progress, each filing type answers different investor questions:
- 10-K and 10-Q – read AI-curated sections on complement immunotherapy pipeline costs and GA launch revenues.
- 8-K – understand pivotal study top-lines without decoding statistical tables.
- Form 4 – monitor leadership confidence through Apellis Pharmaceuticals Form 4 insider transactions real-time.
- DEF 14A – see how proxy statement executive compensation aligns with trial milestones.
Whether you’re analyzing capital needs, assessing competitive risk, or simply wanting Apellis Pharmaceuticals SEC filings explained simply, Stock Titan’s expert analysis turns dense documents into actionable insight so you can focus on decisions, not document hunting.
Apellis Pharmaceuticals, Inc. (APLS)5,000 shares of common stock at a price of $20.06 per share in a transaction coded as a sale. The filing states this was a scheduled sale under a Rule 10b5-1 trading plan dated March 3, 2025.
After this transaction, David Watson beneficially owns 108,730 shares of Apellis common stock directly. He also reports indirect ownership of 10,000 shares through a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals (APLS) reported a profitable Q3 2025 driven by a major collaboration payment. Total revenue was $458.6 million versus $196.8 million a year ago. Product revenue was $177.8 million (SYFOVRE $150.9 million; EMPAVELI $26.8 million). Licensing and other revenue rose to $280.8 million, reflecting a $275.0 million upfront from Sobi under a royalty buy‑down effective July 1, 2025.
The company posted net income of $215.7 million (diluted EPS $1.67), compared to a net loss last year. Cash and cash equivalents were $479.2 million, with accounts receivable at $345.5 million. On the balance sheet, a senior secured credit facility had a $375.0 million principal balance, and $93.9 million of convertible notes remained outstanding, reclassified as current as they mature on September 15, 2026. The FDA approved EMPAVELI for C3G and IC‑MPGN on July 28, 2025, expanding its rare disease indications. As of October 23, 2025, shares outstanding were 126,525,218.
Apellis Pharmaceuticals (APLS) reported an insider transaction by CFO Timothy Sullivan. On October 21, 2025, he exercised stock options for 10,000 shares at $10.03 and sold 10,000 shares at $28.03 under a Rule 10b5-1 trading plan.
After these transactions, he held 110,936 shares directly and 60,396 shares indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. He also reported 232,903 derivative securities (stock options) beneficially owned following the transactions.
Apellis Pharmaceuticals (APLS) General Counsel David Watson reported a sale of 5,000 shares of common stock at $25.22 on 10/16/2025 pursuant to a Rule 10b5-1 trading plan dated March 3, 2025.
After the transaction, he beneficially owned 113,730 shares directly, plus 10,000 shares held indirectly via a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023.
Apellis Pharmaceuticals (APLS): Director insider activity reported on Form 4. On 06/24/2025, the reporting person transferred 4,787 shares for no consideration to Epidarex. On 10/10/2025, Epidarex sold 31,092 shares at a weighted average price of $23.7211 under a Rule 10b5-1 trading plan adopted on June 20, 2025. Following the sale, 3,837 shares were held indirectly via Epidarex, then distributed for no consideration, resulting in 0 shares held indirectly. Direct ownership after the 06/24 transfer was 153,606 shares.
Apellis Pharmaceuticals director Dunlop A. Sinclair reported multiple dispositions of Apellis common stock on 09/30/2025. The filing shows a sale of 31,092 shares at a weighted average price of $22.58 (individual sale prices ranged from $22.23 to $22.74). The filer states these sales were executed under a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on June 20, 2025. The report lists an additional 3,837-share distribution at no consideration and includes a separate disposition line showing 158,393 shares disposed, without price detail in the table. Sinclair is identified as a director and as having indirect ownership through Epidarex, which holds voting and dispositive power over the shares.
Dunlop A. Sinclair, a director of Apellis Pharmaceuticals (APLS), reported multiple dispositions of Apellis common stock on 09/19/2025. Sales include 31,092 shares sold under a Rule 10b5-1 plan at a weighted-average price of $22.95 (execution prices ranged $22.73–$23.27). A separate distribution of 3,837 shares was recorded as a stock distribution for no consideration. The reported holdings after the first two transactions were 68,908 and 65,071 shares, respectively, held indirectly through Epidarex Capital I LP, of which Sinclair is a general partner and may be deemed to have voting and dispositive power. The Form 4 was signed by an attorney-in-fact on behalf of Sinclair.
Apellis Pharmaceuticals (APLS) filing a Form 144 shows a proposed sale of 93,276 shares of common stock for an aggregate market value of $2,140,917.00, to be executed through Stifel Nicolaus & Company on Nasdaq on 09/19/2025. The shares were acquired in three tranches: 62,441 shares on 08/21/2013, 31,478 shares on 12/24/2015, and 6,081 shares on 08/07/2017; all were paid in cash to the issuer. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
David O. Watson, General Counsel of Apellis Pharmaceuticals (APLS), reported a sale of 5,000 shares of Apellis common stock on 09/16/2025 at a price of $24.34 per share under a 10b5-1 trading plan dated March 3, 2025. After the reported transaction, Mr. Watson beneficially owns 118,730 shares directly. The filing also discloses 10,000 shares held in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of any pecuniary interest. The Form 4 was signed on 09/18/2025.
Apellis Pharmaceuticals insider James G. Chopas, the company's VP and Chief Accounting Officer, reported a small sale of 189 shares of Apellis common stock on 09/15/2025 at a price of $24.192 per share. The filing states the shares were sold to cover tax withholding related to Restricted Stock Units that vested on 09/12/2025. After the transaction, Mr. Chopas beneficially owned 53,468 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
FAQ
What is the current stock price of Apellis Pharmace (APLS)?
What is the market cap of Apellis Pharmace (APLS)?
